As of November 7, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Pacific Biosciences Of Calif. The largest reported stake is T. Rowe Price Associates, Inc.'s, at 10.8%. 8 filings are on record since July 24, 2025 (Schedule 13G, November 6, 2026).
Sell to companies like Pacific Biosciences Of Calif? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: T. Rowe Price Associates, Inc. · Sole voting: 33,437,007 · Shared voting: 0 · Sole dispositive: 33,445,993 · Shared dispositive: 0 · SCHEDULE 13G, 2026-11-06
- · Reporting person: ARK Investment Management LLC · Sole voting: 27,781,961 · Shared voting: 327,377 · Sole dispositive: 29,781,416 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: The Vanguard Group · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-03-27
- · Holder: ARK Investment Management LLC · Percent: 12.34% · SCHEDULE 13G/A
- · Reporting person: Madrone Capital Partners, LLC · Sole voting: 0 · Shared voting: 4,976,089 · Sole dispositive: 0 · Shared dispositive: 4,976,089 · SCHEDULE 13G/A, 2025-11-14
Pacific Biosciences Of Calif has 8 Schedule 13D or 13G filings on record since 2025-07-24. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: about 40 jobs, latest 2026-08-05 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 10.8% | 33,445,993 | SCHEDULE 13G, 2026-11-06 | 2026-10-31 |
| ARK Investment Management LLC | 9.59% | 29,781,416 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Edmond De Rothschild Asset Management (France) | 4.5% | 13,366,200 | SCHEDULE 13G/A, 2025-07-24 | 2025-06-30 |
| 2.8% | 8,476,089 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 | |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Pacific Biosciences Of Calif and the warning signs.
Free to see. No signup.
Keep reading
More on Pacific Biosciences Of Calif and the records around it.
Pacific Biosciences Of Calif elsewhere on the record
- Leadership changes Aug 2026
- Layoff notices Aug 2026
- Who owns it
Companies that share a holder
- EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE) also filed stake reports on 1 other company: ZipRecruiter, Inc. (Apr 2026)
- ARK Investment Management LLC also filed stake reports on 20 other companies: Tempus AI, Inc. (Nov 2026), 10x Genomics, Inc. (Oct 2026), Twist Bioscience Corp (Sep 2026)
- T. Rowe Price Associates, Inc. also filed stake reports on 191 other companies: APARTMENT INVT & MGMT CO -A (Oct 2026), BETA BIONICS INC (Oct 2026), 10X GENOMICS INC-CLASS A (Sep 2026)
Watch Pacific Biosciences Of Calif
Get an email when Pacific Biosciences Of Calif files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Pacific Biosciences Of Calif?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Pacific Biosciences Of Calif: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pacific Biosciences Of Calif covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 33,437,007 | 0 | 33,445,993 | 0 | SCHEDULE 13G, 2026-11-06 |
| ARK Investment Management LLC | 27,781,961 | 327,377 | 29,781,416 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Catherine D. Wood | 0 | 28,109,338 | 0 | 29,781,416 | SCHEDULE 13G/A, 2026-08-14 |
| Madrone Capital Partners, LLC | 0 | 4,976,089 | 0 | 4,976,089 | SCHEDULE 13G/A, 2025-11-14 |
| Madrone Opportunity Fund, L.P. | 0 | 4,976,089 | 0 | 4,976,089 | SCHEDULE 13G/A, 2025-11-14 |
| Shimoda Holdings, LLC | 0 | 3,500,000 | 0 | 3,500,000 | SCHEDULE 13G/A, 2025-11-14 |
| Gregory Boyd Penner | 0 | 8,476,089 | 0 | 8,476,089 | SCHEDULE 13G/A, 2025-11-14 |
| Jameson J. McJunkin | 0 | 4,976,089 | 0 | 4,976,089 | SCHEDULE 13G/A, 2025-11-14 |
| Thomas Patterson | 0 | 4,976,089 | 0 | 4,976,089 | SCHEDULE 13G/A, 2025-11-14 |
| The Vanguard Group | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-03-27 |
The latest filing identifies Pacific Biosciences Of Calif by CUSIP 69404D108 and gives its principal executive office as 1305 O'BRIEN DRIVE, MENLO PARK, CA 94025 (SCHEDULE 13G, 2026-11-06).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference.Gregory Boyd Penner, SCHEDULE 13G/A, 2025-11-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-24 | Edmond De Rothschild Asset Management (France) | 4.5% | SCHEDULE 13G/A |
| 2025-08-13 | Gregory Boyd Penner | 6.8% | SCHEDULE 13G/A |
| 2025-11-04 | ARK Investment Management LLC | 10.3% | SCHEDULE 13G/A |
| 2025-11-14 | Gregory Boyd Penner | 2.8% | SCHEDULE 13G/A |
| 2026-02-03 | ARK Investment Management LLC | 12.34% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-08-14 | ARK Investment Management LLC | 9.59% | SCHEDULE 13G/A |
| 2026-11-06 | T. Rowe Price Associates, Inc. | 10.8% | SCHEDULE 13G |
Questions about who owns Pacific Biosciences Of Calif
Who owns Pacific Biosciences Of Calif?
On this page, 2 holders' latest ownership filings report 5% or more of Pacific Biosciences Of Calif: T. Rowe Price Associates, Inc. (10.8%, Schedule 13G, filed 2026-11-06) and ARK Investment Management LLC (9.59%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Pacific Biosciences Of Calif?
By the share each holder's latest filing reports, the largest holders of Pacific Biosciences Of Calif on this page are T. Rowe Price Associates, Inc. (10.8%) and ARK Investment Management LLC (9.59%).
When did T. Rowe Price Associates, Inc. buy into Pacific Biosciences Of Calif?
The filings give report dates, not purchase dates. The earliest filing from T. Rowe Price Associates, Inc. on this page is the Schedule 13G, filed 2026-11-06, reporting 10.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Pacific Biosciences Of Calif
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 4, 2026 | Leadership change: Bill Meyer appointed, Chief Accounting Officer | — | Leadership changes | Source |
| August 5, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| July 9, 2026 | Leadership change: Christopher M. Smith departs, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Pacific Biosciences Of Calif. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.